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Background: Alzheimer’s disease (AD) is characterized by cerebral deposition of β-amyloid peptide (Aβ). Aβ is
produced by sequential cleavage of the Amyloid Precursor Protein (APP) by β- and γ-secretases. Many studies have
demonstrated that the internalization of APP from the cell surface can regulate Aβ production, although the exact
organelle in which Aβ is produced remains contentious. A number of recent studies suggest that intracellular
trafficking also plays a role in regulating Aβ production, but these pathways are relatively under-studied. The
goal of this study was to elucidate the intracellular trafficking of APP, and to examine the site of intracellular
APP processing.
Results: We have tagged APP on its C-terminal cytoplasmic tail with photoactivatable Green Fluorescent Protein
(paGFP). By photoactivating APP-paGFP in the Golgi, using the Golgi marker Galactosyltranferase fused to Cyan
Fluorescent Protein (GalT-CFP) as a target, we are able to follow a population of nascent APP molecules from the
Golgi to downstream compartments identified with compartment markers tagged with red fluorescent protein
(mRFP or mCherry); including rab5 (early endosomes) rab9 (late endosomes) and LAMP1 (lysosomes). Because
γ-cleavage of APP releases the cytoplasmic tail of APP including the photoactivated GFP, resulting in loss of
fluorescence, we are able to visualize the cleavage of APP in these compartments. Using APP-paGFP, we show that
APP is rapidly trafficked from the Golgi apparatus to the lysosome; where it is rapidly cleared. Chloroquine and the
highly selective γ-secretase inhibitor, L685, 458, cause the accumulation of APP in lysosomes implying that APP is
being cleaved by secretases in the lysosome. The Swedish mutation dramatically increases the rate of lysosomal
APP processing, which is also inhibited by chloroquine and L685, 458. By knocking down adaptor protein 3
(AP-3; a heterotetrameric protein complex required for trafficking many proteins to the lysosome) using siRNA, we
are able to reduce this lysosomal transport. Blocking lysosomal transport of APP reduces Aβ production by more
than a third.
Conclusion: These data suggests that AP-3 mediates rapid delivery of APP to lysosomes, and that the lysosome is a
likely site of Aβ production.
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AD is the leading cause of dementia in adults [1]. A
neuropathological hallmark of AD is the accumulation
of β-amyloid (Aβ) in plaques in the brain [2]. Aβ is
produced through sequential cleavage of amyloid precur-
sor protein (APP) by secretases. Cleavage by β-secretase
removes the N-terminal ectodomain, leaving a 99 residue
C-terminal fragment (CTF) containing Aβ [3–5]. The
CTF is then processed by γ-secretase [6] to produce Aβ
species ranging from 39–43 residues in length [7]. The 42
amino acid form of Aβ (Aβ42) has a higher propensity to
aggregate, is more toxic in cell culture experiments and is
the dominant component of amyloid plaques [8–11].
Many experiments suggest that the production of Aβ
occurs in the endosomal/lysosomal system. Work in our
laboratory has demonstrated that lysosomes are highly
enriched in APP and γ-secretase proteins (composed of
at least presenilin, APH1, PEN-2 and nicastrin) and γ-
secretase activity (the ability to cleave APP to produce Aβ)
[12,13]. Others have also described APP and γ − secretase
activity in lysosome-related autophagosomes and phago-
somes [14,15]. In agreement with these findings, deacidifi-
cation of the endosomal/lysosomal system decreases Aβ
production [16,17]. When proteolysis is blocked with pro-
tease inhibitors or by presenilin knock-out (which abol-
ishes γ-secretase activity), amyloidogenic fragments of
APP accumulate in lysosomes [18–20].
While many studies have shown that endocytosis of
APP is crucial for Aβ production [21–23], a number of
studies have suggested that the intracellular trafficking
of APP might also play an important role in Aβ gener-
ation. For example, Aβ production is decreased in MDCK
cells when APP is sorted to the basolateral membrane
[24]. More recent studies demonstrate that Aβ production
is decreased by retrograde sorting of APP from endosomes
to the trans-Golgi network (TGN) [25–28]. Because the
TGN serves as sorting station for nascent cargo from the
ER and protein recycled from endosomes [29], an under-
standing the trafficking of APP into and out of the Golgi
will increase our understanding of Aβ production.
While cell-surface proteins are amendable to many
labeling techniques, intracellular proteins are more diffi-
cult to track. Photoactivatable-Green Fluorescent Protein
(paGFP) has provided a new tool to examine intracellular
trafficking. paGFP is a form of GFP that has low basal
fluorescence, but develops strong, stable green fluores-
cence after being activated by 413 nm laser light [30,31].
Constructs using paGFP [30,32] have been used to exam-
ine the turnover of peroxisomes [33] and autophagosomes
[34] and to examine actin dynamics in neuronal dendritic
spines [35].
Fluorescent protein tags have previously been used to
examine movement of APP containing vesicles [36,37],
including tubular-vesicular structures emanating fromthe Golgi apparatus [38]. APP-paGFP constructs have
been used to visualize APP undergoing fast axonal trans-
port [39] and to image the trafficking of APP out of the
perinuclear region, although these authors did not iden-
tify the compartments involved [28,40].
Our aim was to examine the trafficking of APP from
the Golgi apparatus and to identify downstream com-
partments and identify sites of cleavage. We used tar-
geted activation of APP-paGFP in the Golgi apparatus
(identified using Galactosyltransferase fused to Cyan
Fluorescent Protein (GalT-CFP) [41], and followed acti-
vated APP-paGFP using confocal microscopy fluores-
cence imaging to intracellular compartments labeled
with compartment marker proteins fused to red fluores-
cent proteins including rab5 (early endosomes) [42–44],
rab9 (late endosomes) [45,46] and LAMP1 (lysosomes)
[47,48]. Tracking the disappearance of green fluorescent
APP-paGFP from these downstream compartments al-
lows us to examine the intracellular site of cleavage and
degradation; essentially performing pulse chase experi-
ments in single cells. Surprisingly, we show that a large
fraction of APP traffics rapidly to LAMP1-labeled lyso-
somes within seconds after photoactivation in the Golgi,
and is subsequently cleaved by a γ-secretase-like activ-
ity. This pathway is mediated by an interaction between
APP and Adaptor Protein 3 (AP-3). Knocking down AP-
3 blocks lysosomal transport and reduces Aβ secretion
into the media for more than one third. This suggests
that direct lysosomal transport of APP is an important
source of Aβ.
Results
APP-paGFP can be followed as it traffics from the Golgi
apparatus to LAMP1-labeled compartments
In order to study the intracellular trafficking of APP
from the Golgi apparatus in live cells, we generated ex-
pression constructs (Figure 1) containing full length APP
(FL-APP) fused to an N-terminal HA epitope tag and
photoactivatable Green Fluorescent Protein (paGFP) at its
C-terminal cytoplasmic tail. To avoid any confounding ef-
fects of uncharacterized N-terminal APP cleavage and
sorting signals [49] we also examined a shortened con-
struct (referred to as βAPP) fused to the C-terminal 112
amino acids of APP containing both the β- and γ-cleavage
sites. This construct also contains an N-terminal HA-
epitope tag. βAPP-CFP colocalizes with full length
FL-APP-GFP and has the same subcellular distribution
as endogenous APP in primary neurons [50]. These
constructs are cleaved by secretases (Additional file 1:
Figure S1) and produce Aβ (ELISA data below). In fixed
cells, the N-terminal HA-tag of these constructs are well
colocalized with the C-terminal Fluorescent protein tag,
implying that much of the intracellular APP is trafficked
before cleavage (Additional file 2: Figure S2). We have
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Figure 1 Overview of constructs. For these experiments, APP constructs were generated including the full length APP 751 fused to paGFP on its
C-terminus. A shorter construct consisting of the C-terminal 112 amino acids of APP fused to paGFP. Both constructs include a linker with includes
an N-terminal HA epitope tag, and both constructs contain α-, β- and γ- cleavage sites. Cleavage at the γ-site will release the C-terminal tail of APP
along with the paGFP tag into the cytoplasm.
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are also trafficked to the cell surface and internalized to
endosomes and lysosomes [50]. After photoactivation of
βAPP-paGFP and FL-APP-paGFP constructs, regions or
compartments exhibiting APP accumulation of Golgi-
derived APP will therefore appear as regions of in-
creased green fluorescence. At sites where γ-cleavage
occurs, cleavage will release the APP C-terminal and its
paGFP tag into the cytoplasm, decreasing the fluores-
cent signal over time.
These studies were performed in the SN56 cell line, an
easily transfectable cholinergic cell line [51,52]. For each
experiment, SN56 cells were co-transfected with an APP-
paGFP construct along with a marker of the Golgi appar-
atus (GalT-CFP) [41] and subcellular compartment marker
fused to a red fluorescent protein (mRFP or mCherry).
Compartment markers were LAMP1 (lysosomes), Rab5
(early endosomes) and Rab9 (late endosomes). LAMP1
is a 120kDa protein that is localized to the limiting
membrane of lysosomes [47,48]. Rab5 localizes to the
early endosomal membrane and is involved in homoe-
genous or heterogenous vesicle fusion [42–44]. Rab9
localizes to late endosomal membrane and evidence
suggests that Rab9 is involved in returning cargo from
the late endosome to the Golgi [45,46]. Although many
authors use rab7 as a late endosomal marker, rab7 also
labels lysosomes extensively [53]. Cells with normal
morphology, no inclusions, and normal distribution of
compartment marker expression were imaged live on a
Zeiss LSM510 laser scanning confocal microscope. Re-
gions of interests (ROIs; the irradiation targets, typically
0.1-0.2 μm2) were drawn on the Golgi apparatus using the
Zeiss Physiology package. During a 15-minute photoacti-
vation period, cells were alternately imaged and then
briefly irradiated with 405 nm laser light (25 mW) for 20iterations (typically 2 seconds) within each of the ROI’s to
photoactivate APP-paGFP to produce a video time course.
The irradiation targets were carefully monitored through-
out the experiments to ensure that they did not drift
outside the Golgi apparatus. Because of the very small
irradiation targets, and APP’s rapid movement through
the Golgi apparatus, multiple rounds of photoactivation
were required to create a strong green fluorescent sig-
nal. Images were acquired after each photoactivation
cycle, approximately every 30 seconds, and colocaliza-
tion analysis was performed using Imaris software
(Bitplane). After the initial photoactivation period, cells
were imaged for up to an hour to follow the movement
of APP out of the Golgi and its clearance.
When we started these experiments, we expected that
APP to move primarily to the cell surface and then to be
internalized into lysosomes after 30 minutes to 1 hour. In-
stead, within seconds of photoactivation, activated bright
green fluorescent APP-paGFP colocalized with LAMP1-
mRFP, implying rapid transport to lysosomes. A typical
experiment is shown in Additional file 3: Video S1, where
βAPP-paGFP from the Golgi apparatus (blue) and can be
seen moving within seconds to lysosomes (red). After
15 minutes of alternately photoactivating and imaging,
cells were imaged (chased) for a further hour. During the
chase period most of the green fluorescent APP disap-
peared, suggesting that it was being cleared.
In these experiments, photoactivated both FL-APP-
paGFP and βAPP-paGFP appear to be rapidly colocalized
with LAMP-1 compartment (Figure 2a; top and middle
panels). To confirm that this trafficking occurs in neurons,
we then transfected GalT-CFP, βAPP-paGFP and LAMP1-
mRFP into primary mouse cortical neurons. After photo-
activating βAPP-paGFP in the Golgi, green fluorescence
appears within 30 seconds to a minute in LAMP1-mRFP
Figure 2 APP is rapidly trafficked from the Golgi apparatus to LAMP1-labeled compartment. Photoactivation targets were drawn on the
Golgi apparatus (white dots with arrows). For 15 minutes, cells were alternately imaged and irradiated (photoactivated) with 405 nm laser light
within the targets. White arrowheads point to APP-paGFP colocalized with Lamp1-mRFP. Scale Bar = 5 μm. a) Demonstrates rapid transport of
Full length-APP- paGFP (top panel) and βAPP-paGFP (middle panel) from Golgi apparatus to a LAMP1-labeled compartment. The same trafficking
occurs in mouse primary neurons (lower panel). (See Additional file 3: Video S1). b) Higher magnification images of βAPP-paGFP trafficking
rapidly to a LAMP1 labeled compartment. Scale Bar = 1 μm. c) Comparison of the colocalization of activated FL-APP-paGFP (n = 9) and activated
βAPP-paGFP (n = 8). d) SN56 cells transiently transfected with the secretory protein Vesicular Stomatitis Virus Glycoprotein-paGFP (VSVG-paGFP),
GalT-CFP (blue), and LAMP1-mRFP (red) to demonstrate that very little of the green photoactivated VSVG-paGFP arrives in the LAMP1 compartment;
paGFP does not alter trafficking. Scale bars = 5 μm. e) Transfected SN56 cells were treated for 5 minutes with nocodazole before imaging
(See Additional file 5: Video S2) Scale bars = 5 μm. f) Z-stack of the same cell taken immediately following 15 minutes of photoactivation
demonstrating that green signal remains inside the Golgi.
Tam et al. Molecular Brain 2014, 7:54 Page 4 of 18
http://www.molecularbrain.com/content/7/1/54labeled compartments. (Figure 2a; bottom panel). To fur-
ther demonstrate that the LAMP1 compartment rapidly
received photoactivated APP-paGFP, we performed im-
aging at high magnification in closely cropped cells with
βAPP-paGFP. In the earliest time points, it was possible to
observe green fluorescent APP-paGFP arriving rapidly
within LAMP1 compartments (Figure 2b). We quantitated
the fraction of fluorescent activated paGFP colocalized
with LAMP-mRFP after 15 minutes of photoactivation,
we found that 34.14 ± 5.10% (Mean ± SEM) of FL-APP
and 34.70 ± 4.05% of βAPP was colocalized with LAMP1
(not statistically different) (Figure 2c). Because the traffick-
ing of the shorter construct was indistinguishable and re-
sulted in brighter images, the βAPP-paGFP construct wasused for the remainder of these experiments. Enlarged im-
ages from these experiments along with colocalization
analysis is shown in Additional file 4: Figure S3. These im-
ages are very similar to the trafficking of LAMP1-paGFP
from the Golgi to lysosomes produced by Lippincott-
Schwartz [30].
To rule out the possibility that transport to LAMP1
compartment was due to overexpression or the paGFP
tag, we examined the transport of the Vesicular Stoma-
titis Virus Glycoprotein (VSVG); a classic secretory traf-
ficking protein. VSVG was tagged with paGFP at its
cytoplasmic C-terminal [54,55] similarly to our APP
constructs. We transfected SN56 cells VSVG-paGFP.
These cells were subjected to the same imaging protocol
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pulse-period, VSVG-paGFP appeared on the cell surface
and exhibited minimal transport to a LAMP1 compart-
ment (Figure 2d), in concordance with previous results
[32,55]. Therefore, we conclude the paGFP tag did not
alter the trafficking of APP.
To verify the accuracy of βAPP-paGFP photoactivation
in the Golgi apparatus and that we were not photoacti-
vating βAPP-paGFP in nearby structures, SN56 cells
were transfected with GalT-CFP, βAPP-paGFP and
LAMP1-mRFP and pretreated with nocodazole and/or
cytocholasin D to block transport out of the Golgi [56].
Cells were then photoactivated and imaged for 15 mi-
nutes using the Golgi apparatus marker GalT-CFP as a
target, and a Z-stack was taken immediately after the
photoactivation period. During the entire experiment,
photoactivated APP-paGFP remained almost exclusively
within the Golgi apparatus (Figure 2e; Additional file 5:
Video S2). Inspection of the post-irradiation Z-stack also
revealed that photoactivated βAPP-paGFP was localized
principally within the Golgi apparatus, with almost no
fluorescence evident in other compartments or at the
cell surface (Figure 2f ).
APP-paGFP traffics preferentially to lysosomes from the
Golgi apparatus
Next, we examined APP trafficking from the Golgi ap-
paratus to early and late endosomes. In these experi-
ments, βAPP-paGFP was co-transfected with GalT-CFP
along with either rab5- mRFP (early endosomes) or
rab9-mCherry (late endosomes). Rab5 is highly associ-
ated with early endosomal membranes and is routinely
used as a marker for early endosomes [42,43]. Rab9 lo-
calizes to late endosomal membrane and evidence sug-
gests that Rab9 is involved in returning cargo from the
late endosome to the Golgi [45,46,53]. Rab7 is also a lateFigure 3 APP is primarily transported to a LAMP1 compartment. SN56 c
(blue), and a compartment marker (red). Photoactivation targets were drawn
was visualized from the from Golgi apparatus to Rab 9 labelled late endosom
c) Percent of APP-paGFP fluorescence colocalized with respective compartme
LAMP1 (n = 9), squares: Rab9 (n = 10), triangles: Rab5 (n = 7)). Error bars represendosomal marker [45], but Rab7 also defines a popula-
tion of lysosomes [53]. Therefore, to avoid confounding
late endosomes with lysosomes we chose Rab9 as our
late endosomal marker.
Cells were then alternately irradiated with 405 nm
within targets placed over the Golgi apparatus and im-
aged to produce a time course of images. In these exper-
iments, a small amount of βAPP-paGFP can be seen
colocalizing with Rab9 and Rab5 (Figure 3a and b; re-
spectively) at the end of the photoactivation period. At
the end of the 15-minute pulse period, 36.57 ± 4.69%
(Mean ± SEM) of photoactivated βAPP-paGFP coloca-
lized with LAMP1 labeled compartments. Trafficking to
rab9 and rab5 compartments was significantly lower at
17.39 ± 4.37% and 5.84 ± 3.05% respectively (Figure 3c).
Although some LAMP1 labeling is found in early and
late endosomes, the fact that significantly more APP was
co-localized with LAMP1 than rab5 or rab9 suggests
that APP is in bona fide lysosomes.
APP-paGFP is cleaved in a LAMP1 positive compartment
Subcellular fractionation has shown that γ-secretase pro-
teins and APP are bona fide residents of the lysosomal
membrane [13]. Furthermore, in vitro assays revealed
that γ-secretase has an acidic optimal pH (4.5-5) [13].
Therefore, we hypothesized that inhibiting γ-secretase or
lysosomal enzyme function could inhibit both secretase
cleavage and nonspecific degradation of βAPP, which
would result in paGFP fluorescence accumulation at the
lysosome membrane. Therefore, we followed the extinction
of paGFP fluorescence from LAMP1 positive vesicles after
the end of the photoactivation period. We found that there
was nearly complete extinction of photoactivated βAPP-
paGFP (Figure 4a; Additional file 3: Video S1) and FL-
APP-paGFP (not shown) fluorescence from the LAMP1
compartment within 1 hour. First we examined the effectsells were cotransfected with plasmids expressing APP-paGFP, GalT-CFP
on the Golgi apparatus (white dots with arrows). βAPP-paGFP trafficking
es (a) and Rab 5 labelled early endosomes (b). Scale bars represent 5 μm.
nt markers after 15 minutes of photoactivation in the Golgi (circles:
ent standard deviation. (* = p < 0.05).
Figure 4 APP is processed in the lysosome by a γ-secretase like activity. SN56 cells were transiently transfected with βAPP-paGFP, GalT-CFP,
and LAMP1-mRFP. Cells were alternately photoactivated with 405 nm light and imaged in the Golgi for 15 minutes, and then imaged every
30 seconds for 1 hour. a) Shows the accumulation of photoactivated APP-paGFP in the lysosome after 15 minutes, follow by its near complete
clearance after 45 minutes. Arrowheads denote areas of colocalization. (See also Additional file 3: Video S1) b) Transiently transfected SN56 cells
were pretreated with 100 μM chloroquine for 30 minutes prior to imaging. After chloroquine treatment APP is still visible in lysosomes after 45
minutes (See Additional file 6: Video S3). c) Cells treated with 0.5 μM L685, 458 (γ-secretase inhibitor) overnight prior to photoactivating/imaging.
L685, 458 treatment substantially increases the accumulation of photoactivated βAPP-paGFP in lysosomes, and substantially decreases its cleance.
Scale bars represent 5 μm (See Additional file 7: Video S4). d) Cleavage of βAPP-paGFP was determined by measuring the loss of FL-APP (black
open triangles) and βAPP-paGFP (black closed circles) from LAMP1 labeled compartments. Values were averaged and normalized to begin at
100%. Overlaid in green squares is the loss of fluorescence of EGFP in the identical imaging protocol. Error bars represent SEM. (* = p < 0.05)
(e) Shows the clearance of photoactivated APP-paGFP cells that were treated with 100 μM chloroquine for 30 minutes before imaging (n = 9) or
with 0.5 μM L685, 458 (γ-secretase inhibior) (n = 9). Error bars represent SEM.
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quine. Chloroquine has been reported to alkalinized the
endosomal/ lysosomal system and to inhibits APP clear-
ance and Aβ production [17,57,58]. Cells were acutely
treated with 100 μM chloroquine for 30 minutes before
imaging. The increase in pH was confirmed by loss of
LysoSensor Green signal (a pH dependent fluorescent
probe, Invitrogen) from LAMP1 compartments (data
not shown). As in the untreated control cells, βAPP-
paGFP fluorescent signal was observed trafficking dir-
ectly from the Golgi apparatus to LAMP1-mRFP labeled
lysosomes (Figure 4b, Additional file 6: Video S3). How-
ever, cells treated with chloroquine accumulated fluor-
escent green photoactivated βAPP-paGFP in LAMP1
labeled compartments.
Next we assessed the ability of the highly potent and
specific γ-secretase inhibitor L685,458 [59] to block the
cleavage of βAPP-paGFP. SN56 cells were pretreated with
0.5 μM of L685,458 for 24 hours before imaging. L685,458
treatment caused marked accumulation photoactivated
βAPP-paGFP in lysosomes during the photoactivation
phase, and significantly reduced the clearance of APP
from lysosomes. (Figure 4c; Additional file 7: Video S4).
We hypothesized that if APP were cleaved at the lyso-
somal membrane by secretase enzymes, the cytoplasmic
tail of APP along with activated paGFP would be re-
leased into the cytoplasm resulting in loss of fluores-
cence from this compartment. Furthermore, this processwould appear with first order kinetics. To quantitate
APP-paGFP clearance from the lysosome after the photo-
activation period, we measured the number of pixels of
APP-paGFP fluorescence colocalized with LAMP1-mRFP
using Imaris software for each time point, normalizing the
highest value of colocalization (after the photoactivation
period) to 100%. In these experiments, FL-APP-paGFP
and βAPP-paGFP disappear from the lysosomes with non-
linear kinetics. The disappearance of βAPP-paGFP was
modeled using Prism 5 (GraphPad, La Jolla, CA) from the
lysosome can be accurately modeled using the integrated
rate equation for a first order reaction (k = 0.00153,
r2 = 0.96) (Figure 4d). This suggests that APP is cleaved
enzymatically in lysosomal compartments.
Because of our long imaging protocol, some of the loss
fluorescence from activated paGFP could be the result of
photobleaching. Therefore, we constructed photobleach-
ing curves using enhanced-GFP (EGFP), as EGFP and
paGFP have nearly identical photobleaching characteristics
[30]. SN56 cells were transiently transfected with EGFP,
and fixed with 4% paraformaldehyde. Cells were then im-
aged using the same imaging protocol, as in the previous
live cell imaging experiments. The normalized number of
green pixels at each time point was quantitated, and plot-
ted on the same graph as our βAPP-paGFP clearance data
(Figure 4d). βAPP-paGFP fluorescence decayed faster and
became significantly lower than GFP fluorescence (One-
way ANOVA; Tukey’s Post Hoc; p < 0.05). Therefore, the
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of a first order enzymatic reaction (Figure 4d).
Next, we quantitated the effect of inhibitors on APP
clearance (Figure 4e). After chloroquine treatment, photo-
activated APP-paGFP in the lysosome decreased linearly
over time during the chase phase, suggesting that it was
not cleared by an enzymatic cleavage. There was no sig-
nificant difference from loss of fluorescence due to photo-
bleaching (One-way ANOVA; Tukey’s Post Hoc p < 0.05)
(Figure 4e). In cells treated with L685,458 or chloroquine,
the loss of βAPP-paGFP fluorescence from lysosomes dur-
ing the chase phase was also not significantly different
from the rate of loss of GFP fluorescence due to photo-
bleaching (One-way ANOVA; Tukey’s Post Hoc; p < 0.05)
(Figure 4e). Cells treated with L685,458 also consistently
exhibited accumulation of photoactivated βAPP-paGFP at
the cell surface (Figure 4c middle and right panels). This
is in agreement with a previous study that showed APP in-
ternalization was decreased by treatment with γ-secretase
inhibitors [60,61]. Our data therefore suggests that βAPP-
paGFP clearance from lysosomes is perfomed by both a
pH-dependent protease (as expected for a β-secretase)
and by the γ-secretase. The accumulation of APP in these
LAMP1 compartments following inhibition of proteases
suggests that they represent terminal lysosomes and not
an endosomal intermediate.
The Swedish mutation dramatically increases APP
clearance from the lysosome, but not the Golgi apparatus
The Swedish mutation (APPsw) is a double mutation at
codons APP 670/671 (numbered in APP695) adjacent to
the β-secreatse cleavage site that increases the rate of β-
cleavage of APP by up to a factor of 10, and has been
suggested to alter the trafficking of APP [22,62,63]. To
examine effect of the Swedish mutation on intracellular
APP trafficking, we transiently transfected SN56 cells
with βAPPsw-paGFP along with plasmids expressing
compartment markers for the Golgi apparatus and lyso-
somes. The same pulse-chase paradigm was performed
on these cells, targeting the GalT-CFP labeled Golgi appar-
atus to photoactivate βAPPsw-paGFP. Unlike cells trans-
fected with the wild type construct, green fluorescence did
not accumulate in cells transfected with βAPPsw-paGFP in
a LAMP1-labeled compartment. Instead, these cells rapidly
developed diffuse green fluorescence throughout the entire
cell body (Figure 5a; Additional file 8: Video S5). The
diffuse cytoplasmic appearance of paGFP fluorescence
suggests that APP is being rapidly cleaved, with the APP
C–terminal fused to paGFP diffusing rapidly into the cyto-
sol. This likely reflects the higher rate of β-cleavage of
Swedish mutation [64,65].
It has previously been suggested that secretase cleav-
age of the APPsw might occur in the Golgi apparatus. In
order to examine APP cleavage in the Golgi apparatus,we repeated this experiment after treating the cells with
nocodazole and cytocholasin D (Figure 5b; Additional
file 9: Video S6). In dramatic contrast to untreated cells,
virtually all of the paGFP fluorescence remains localized
to the Golgi apparatus during the photoactivation period.
Cells were then followed out to 1-hour post photoactiva-
tion, during which most of the green signal remains in the
Golgi apparatus. It was not possible to quantify the clear-
ance of APP from the Golgi apparatus in this experiment,
because of photobleaching of the GalT-CFP marker. Al-
though it is not possible to say from this data that there
is no cleavage of APP in the Golgi apparatus, the Golgi
apparatus does not appear to facilitate the majority of
APP processing.
In order to examine lysosomal processing of βAPPsw-
paGFP, we treated cells with chloroquine and L685,458.
After treatment with chloroquine, there was rapid traf-
ficking of βAPPsw-paGFP signal to the lysosome where
it accumulated in the photoactivation phase and then
gradually decreased in brightness in the chase phase
(Figure 6; Additional file 10: Video S7). This result was
also seen after treatment with the γ-secretase inhibitor
L685, 458 (Figure 6b; Additional file 11: Video S8). The
loss of fluorescence signal in the chase phase as linear
for both of these treatments was not significantly differ-
ent from GFP photobleaching (Figure 6c and 6d). To-
gether, these data suggests that the Swedish mutation
accelerates the cleavage of APP at the lysosomal mem-
brane, but does not have an effect on APP trafficking to
the lysosome.
APP interacts with adaptor protein AP-3
AP-3 is an adaptor protein that is integral to the direct
delivery of lysosomal membrane proteins (LMPs) from
the Golgi apparatus [66–70]. First, we sought to deter-
mine whether APP and AP-3 colocalize in neurons.
Cortical neurons dissected from E15 mice were immu-
nostained (DIV7) for the APP C-terminal and AP-3δ
subunit, demonstrating colocalization. When analyzed
by Imaris, 41.74 ± 2.60% (Mean ± SEM) of APP fluores-
cence was colocalized with AP-3 signal. We then de-
pleted the δ subunit of AP-3 in SN56 cells using siRNA,
as this has been shown to cause instability and degrad-
ation of the entire AP-3 complex [71]. We found that
cells transfected with this siRNA expressed only 22.01 ±
11.98% (Mean ± SD) of the AP-3 δ subunit on Western
blots (p < 0.05), while cells transfected with a control
siRNA showed no significant change in AP-3 δ expression
(Additional file 12: Figure S4a and b). We also observed
this effect by immunostaining; cells transfected with
siRNA (visualized by the Alexa fluor 647 label on the 5′
end of the control oligonucleotide) showed a marked
decrease in AP-3δ staining while untransfected cells, or
cells transfected with fluorescently labelled negative
Figure 5 The Swedish mutation causes rapid clearance of APP from lysosomes. SN56 cells were transiently transfected with βAPPsw-paGFP,
GalT-CFP, and LAMP1-mRFP. Scale bars represent 5 μm. a) βAPPsw-paGFP was photoactivated for 15 minutes in the GalT-CFP labeled compartment,
and chased for 45 minutes. βAPPsw is cleaved nearly instantaneously and appears in the cytoplasm. b) Cells were treated for 5 minutes before
imaging with 66 μM nocodazole and 10 μM cytochalasin. GalT-CFP is false colored red to provide better contrast, and LAMP1-mRFP has been
false coloured blue. Photoactivated βAPPsw-paGFP accumulates in the Golgi and does not appear to be cleaved. c) Cells were treated acutely
with 100 μM chloroquine (See Additional file 10: Video S7) which results in photoactivated βAPPsw-paGFP accumulating in lysosomes. White
arrowheads represent βAPPsw-paGFP colocalized with LAMP1-mRFP d) Cells were treated with 0.5 μM L658, 458 (See Additional file 11: Video S8),
which also causes photoactivated βAPPsw-paGFP to appear in lysosomes. Scale bars represent 5 μm. Quantitation of colocalized green pixels
with LAMP1-mRFP show that the clearance of βAPPsw-paGFP from the lysosome proceeds linearly after treatment with e) chloroquine (n = 8),
or with f) L658, 458 (n = 9). Error bars represent standard deviation.
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Figure S4c).
To determine whether APP and AP-3 interact using
the in situ proximity ligation assay (iPLA) which allows
the study of low affinity interactions in-situ and has
comparable accuracy to co-immunoprecipitation [72,73].
Briefly, iPLA employs species-specific secondary anti-
bodies bearing complementary DNA strands. If the two
antibodies are within 40 nm, the DNA strands will
hybridize, and the resulting sequence can be replicated,
amplified, and labelled with fluorescent oligonucleotides.
Pairs of interacting proteins were detected as red fluor-
escent dots/μm3.
SN56 cells were transfected with βAPP-CFP, and iPLA
was used to determine the proximity of APP and AP-3.
Cells mock transfected or transfected with negative con-
trol siRNA both demonstrate an interaction between
APP and AP-3. Conversely, cells transfected with siRNA
against AP-3 δ showed a marked decrease (approxi-
mately 98%) in fluorescent puncta signifying decreased
interaction (Figure 6b and c).
AP-3 Knockdown Disrupts Trafficking of APP to Lysosomes
We hypothesized that we could disrupt the trafficking of
APP to lysosomes by siRNA mediated knockdown ofAP-3. As a control, we examined the effect of knock-
down AP-1 (both AP-1a and AP-1b isoforms), which
mediate cell surface trafficking, and trafficking to the
basolateral membrane in epithelial cells [74,75] and was
effectively knocked down by siRNA (Additional file 4:
Figure S3). As before, we co-transfected cells with βAPP-
paGFP, GalT-CFP and LAMP1-mRFP with the addition of
siRNA against either AP-1γ, AP-3δ, or a control siRNA. In
cells transfected with active siRNA, a small amount of
fluorescently tagged negative control siRNA was included
as a marker to identify transfected cells. Cells were photo-
activated in irradiation targets placed over the Golgi
apparatus, and transport of APP was imaged over a 15-
minute period and then analyzed for colocalization of
photoactivated APP and LAMP1-mRFP. We found that
cells transfected with control siRNA alone did not
change βAPP-paGFP trafficking to lysosomes, as com-
pared to cells not transfected with siRNA [37.47 ± 4.58%
vs 36.57 ± 4.69%]. However, the siRNA against δ3 re-
duced APP transit to the lysosome to 16.24 ± 2.65% after
15 minutes of photoactivation. AP-1γ KD did not
change the trafficking of APP from the TGN to lyso-
somes (33.86 ± 4.09%; Mean ± SEM) (Figure 7a and b).
Therefore, AP-3 mediates rapid transport of APP to the
lysosome, while AP-1 is not involved in the direct
Figure 6 AP-3δ and APP colocalize and interact. a) E15 mouse neurons were cultured and immunostained with antibodies against AP-3δ
(SA4; red) and APP (APP C-terminal; green). Arrowheads point to colocalized pixels. Scale bars represent 5 μm. Inset shows magnified view of the
cell body. b) Proximity ligation assay (PLA) demonstrates the interaction of APP and AP-3δ. Cells were transiently transfected with βAPP-CFP
with no siRNA, control siRNA or AP-3δ siRNA. Cells were stained with mouse anti- AP-3δ and rabbit anti-APP C-terminal antibodies. These were
detected with secondary antibodies conjugated to complementary DNA sequences. When proteins are within 40 nm, DNA is ligated and
replicated and detected by in-situ fluorescent red dots. AP-3δ siRNA substantially reduces the number of red dots. (scale bars represent 10 μm)
c) Quantification of PLA fluorescent dots in SN56 cells normalized to cell volume (*p < 0.05).
Figure 7 AP-3 mediates direct trafficking of APP to lysosomes. a) SN56 cells were transfected with βAPP-paGFP, LAMP1-mRFP, GalT-CFP, and
either control siRNA, siRNA against AP-3δ mRNA or siRNA against AP-1γ. Cells were alternately photoactivated with 405 nm light and imaged in
the Golgi for 15 minutes (scale bar represents 5 μm). White arrowheads in the merged image (far right panel) denote colocalized pixels. Scale bars
represent 5 μm. b) Percent of βAPP-paGFP colocalizing with LAMP1-mRFP at the end of the 15-minute photoactivation period. (* = p < 0.05; Error
bars represent standard deviation).
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examined here.
To determine the effect of AP-1 KD and AP-3 KD
on APP processing, SN56 cells were transfected with
βAPPsw-CFP and with negative control siRNA, AP-1
siRNA, AP-3 siRNA or a combination of AP-1 and AP-3
siRNAs. Two days after differentiation, culture media
was taken from the cells and analyzed for Aβ40 and
Aβ42 by ELISA (Invitrogen) (Figure 8a). AP-1 siRNA
did not significantly alter the levels of Aβ 40 [106.0% ±
6.7% (mean ± SEM)], as compared to control. AP-3
siRNA and combined AP-3 and AP-1 siRNAs reduced
the levels of Aβ40 53.9 ± 3.3% and 62.6 ± 6.2%, respect-
ively (p < 0.5). For Aβ42 (Figure 8d), the control siRNA
raised Aβ42 production slightly to 113.8 ± 121.6% (not
significant) while siRNAs against AP-1 reduced Aβ42
levels in the media to 75.1 + 14.1% (not significant). In-
hibitory siRNA to AP-3 alone or AP-1 and AP-3 to-
gether reduced the levels of Aβ42 to 64.2 ± 13.4 and
45.74 ± 11.4% respectively (P < 0.5) (Figure 8b). There-
fore, AP-3 KD reduced the levels of Aβ40 and 42 in the
media, and this effect was increased when AP-1 was
knocked down as well.
Discussion
In this work, we demonstrate the use of paGFP to study
the intracellular trafficking of and clearance of APP. While
paGFP has been used before to examine APP trafficking
[28,40,76], this is the first report to follow APP from the
Golgi apparatus into identified downstream compart-
ments and examine its clearance pharmacologically. Al-
though we had expected APP to traffic to the lysosome
primarily via the plasma membrane, instead we observed



































Figure 8 AP-3 mediates processing to Aβ. SN56 cells were transfected w
siRNA against AP-3δ mRNA or siRNA against AP-1γ. a) SN56 cells were co-t
siRNA against AP-1γ, siRNA against AP-1γ and AP-3δ combined, or siRNA a
by ELISA. Experiments were performed 4 times, with each experiment cons
p < 0.05; ** indicates significantly different from control and either AP-1 orseconds, similar to the behavior of LAMP1 [30]. Fur-
thermore, we were able to follow the clearance of
βAPP-paGFP in from lysosomes, essentially performing
a pulse-chase experiment in this organelle in single
cells. We show that βAPP-paGFP is cleared from the
lysosome with first order kinetics, which is faster than
the linear loss of fluorescence observed during photo-
bleaching. The clearance of APP from lysosomes is sen-
sitive to both chloroquine, a nonspecific inhibitor of
lysosomal function, and L684, 458, a specific γ-secretase
inhibitor. The direct trafficking of APP to this LAMP1
positive compartment is decreased by AP-3 knockdown.
The depletion of AP-3 or AP-3 and AP-1 together re-
sults in a substantial reduction of Aβ in the media.
Because intracellular compartment markers localiza-
tions are not absolute, lysosomal markers can be found
in endosomal compartments and vice versa [77,78]. How-
ever, several features suggest that APP is moving to a bona
fide lysosomal compartment. APP appears to be moving
primarily to LAMP1 positive compartments, with less
moving to compartments labeled with Rab5 and Rab9
(early and late) labeled compartments, suggesting that
the main compartment receiving APP is LAMP1 posi-
tive and negative for rab5 and rab9. Furthermore, after
the inhibition of degradation of APP with chloroquine
or L685, 458, APP moves to LAMP1-labeled compart-
ments and accumulates in these compartments, implying
that they are terminal compartments of the endoso-
mal lysosomal system. Furthermore, that AP-3 knock-
down reduces the production and secretion of Aβ42
by 36% and Aβ40 by 47% suggests that the lysosome
is a major site of APP processing and Aβproduction.
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gested that APP primarily moved to the lysosome via the
cell surface [79], however the evidence presented here
suggests APP can traffic intracellularly from the Golgi to
lysosomes. Kuentzel et al. found that less than ~20% of
nascent APP is transported to the plasma membrane
[80], suggesting that this direct lysosomal pathway maybe
a major processing pathway of APP. LMPs are known to
traffic to the lysosome by at least 2 different pathways.
Some LMPs, like lysosomal acid phosphatase, transit first
to the cell surface, and then cycle between the plasma
membrane and endosomes repetitively before transport to
the lysosome [81]. Other proteins, such as LAMP-1, tran-
sit intracellularly from the Golgi apparatus to lysosomes,
without appearing at the cell surface [82,83]. Our work is
in agreement with of Castor et al., who also demonstrated
using a temperature-block paradigm that APP in the Golgi
apparatus rapidly appears in a LAMP1-positive compart-
ment rapidly after being released from the Golgi [84]. APP
now has at least 4 distinct pathways to the lysosome –
one from the cell surface through endocytosis into endo-
somes [85], one directly to lysosomes from the cell surface
[50], one through autophagosomes [86], and finally the
direct transport from the Golgi apparatus demonstrated
here. This suggests that APP is a normal resident Lyso-
somal Membrane Protein.
This work is not intended to minimize the importance
of APP’s cell surface trafficking. Indeed, AP-1 knock-
down, which is predicted to interfere with APP traffick-
ing to the cell surface, is able to substantially reduce Aβ
production indicates that cell surface APP is still a sig-
nificant source of Aβ. APP transiting to the cell surface
is likely not being well visualized in this study for a
number of reasons including: 1) activated APP-paGFP
arriving at the membrane is diluted by a large amount of
non-fluorescent APP already at the membrane, 2) APP
has a relatively short half life at the membrane, estimated
at 10 minutes [21,87] and 3) we are imaging confocal sec-
tions and therefore seeing only a small fraction of the cell
membrane itself. Indeed, Golgi apparatus-photoactivated
βAPP-paGFP becomes visible at the plasma membrane
when internalization is inhibited with a γ-secretase inhibi-
tor [60,61], demonstrating that APP can transit rapidly to
the cell surface [80].
Several studies have suggested the presence of γ-
cleavage in the lysosome. Our own studies have demon-
strated that γ-secretase proteins and activity are present
in highly purified lysosomes. Although many studies
have observed γ-secretase function at neutral pH, we have
found that γ-secretase activity within isolated lysosomal
membranes possesses an acidic optimal pH [13]. Our find-
ings are in agreement with previous findings that show a
marked accumulation of APP in lysosomes after disrup-
tion of lysosomal pH, and inhibit the production of Aβ[17]. Furthermore, many other studies have documented
the accumulation of APP fragments in lysosomes after
inhibition of lysosomal enzymes or inactivation of PS1
[16,18,20,88], suggesting a critical role for lysosomes in
γ-secretase cleavage of APP. However, this is the first
study to visualize accumulation of APP CTFs at the lyso-
somal membrane using a highly selective γ-secretase in-
hibitor [89–91].
Some investigators have suggested that APP (particu-
larly APPsw) undergoes cleavage in the Golgi apparatus
and in post-Golgi vesicles [62,92]. Our data appears to
show APP and APPsw accumulating stably in the Golgi
apparatus when trafficking is blocked pharmacologically.
Although it is impossible to rule out some processing of
APP in the Golgi apparatus with these experiments, these
data suggest that the Golgi apparatus is not a major site of
Aβ production.
It is interesting that chloroquine and L684, 458 pro-
duce similar results. To our knowledge, chloroquine has
never been shown to specifically affect the γ-secretase
directly in cell free assays. Although our own data has
suggests that γ-secretase functions at an acidic pH in the
lysosome [13], most authors use a neutral pH [93] or
mildly acidic pH [94] for this enzyme. However, efficient
γ - secretase function requires the removal of the luminal
domain of APP by β-cleavage [95]. The β-secretase is
known to transit to the late endosomal/lysosomal com-
partments [96,97]. β-cleavage may also be performed by
lysosomal cathepsins [98,99]. With a pH optimum
below 4.5 [5,100], β-secretase (like cathepsins) would
function optimally in the lysosome. Therefore, the accu-
mulation of APP in the lysosome after chloroquine
could be by non-specifically inhibiting a luminal pH
dependent β-secretase or β-like cleaving enzyme, which
then secondarily inhibits γ-cleavage. When β-cleavage is
accelerated by the APPsw mutation, APP-paGFP is
cleared so rapidly that it cannot be imaged in the lyso-
some. This suggests that, rather than being a tightly
controlled regulatory enzyme, the γ-secretase behaves
more like a “proteasome of the membrane” whose job is
to remove transmembrane stubs of proteins from the
membrane [101].
Our results also demonstrate that lysosomal traffick-
ing of APP may be an important mechanism of regulat-
ing APP cleavage. Specifically AP-3 knockdown reduces
lysosomal trafficking of APP from the Golgi apparatus
and reduces Aβ production and this effect is additive
to AP-1 knock down. A wide range of other proteins
likely also likely regulate APP processing by altering
its trafficking including GGA1 [102,103], X11a, Fe65
[104,105], AP-4, [106], VPS35 [25] and SorLa [26–28].
These studies suggest that control of APP processing
by intracellular trafficking may be crucial for regulating
Aβ production.
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These findings may have broad importance for the patho-
physiology of AD. This is because the lysosome’s biochem-
ical milieu and acidic pH make it the ideal environment
for the nucleation of amyloid fibrils [107,108]. In fact, the
lysosome has been proposed to be a site of Aβ aggregate
seeding [109–111]. This development of Aβ aggregates
has been shown to disrupt synapses [112] and membranes
[113], and can lead to lysosomal rupture leading to cell
death [114,115]. Aβ may be secreted in exosomes, which
are intraluminal vesicles released from the endosomal/
lysosomal system [57,116]. Therefore, Aβ and its higher-
order aggregates may be produced, nucleated, and se-
creted from lysosomes. The lysosome sits at a crossroad,
as a site for the production and degradation of Aβ, as well
as its fibrilogenesis. This work points to the importance of
the lysosomal system in APP processing and its regulation
in developing therapeutic treatments for AD.
Materials and methods
Antibodies
Antibodies used were: Rabbit anti-APP C-terminal (1:1000,
Cat. No. A8717; Sigma), mouse anti-HA (1:1000, Cat. No.
12CA5;Roche); AP-3 δ3 subunit- mouse- SA4 (1:1000;
Developmental Studies Hybridoma Bank); mouse anti-γ-
adaptin (Cat No. 610386; BD Bioscience). Secondary anti-
bodies used were donkey anti-mouse HRP (1: 10 000, Cat
No. 711–0350150, Jackson Immunoresearch) and goat-anti
rabbit HRP (1: 10 000; Biorad). α-tubulin was stained using
a mouse monoclonal antibody (Cat No. T5168, Sigma).
For immunostaining, donkey anti-rabbit Alexa Fluor
488 (A-11034; Invitrogen) and goat anti-mouse Alex
Fluor 546 (A-11003; Invitrogen).
Cell culture and transfection
SN56 (a gift from Dr. Jane Rylett) were grown in Dulbecco's
Modified Eagle medium (DMEM) (Gibco) supplemented
with 10%v/v of fetal bovine serum (FBS; Gibco) and
50 μg/ml of penicillin/streptomycin (P/S), in 5% CO2 at
37°C. Cells were split every 3 days. For confocal studies,
5 × 105 cells were seeded on glass-bottomed culture
dishes (MatTek) the day before transfection in DMEM
supplemented with 10% FBS. Cells were transiently
transfected using Lipofectamine (Invitrogen) according
to manufacturer’s instructions. To differentiate the cells,
the media was replaced 24 hours after transfection with
DMEM supplemented with 50 μg/ml P/S and 1 mM
dibutyryl cyclic AMP (dbcAMP; Sigma). Cells were differ-
entiated for 24 hours and imaged or harvested. Primary
cortical neurons were prepared from embryonic day 15
CD1 mouse embryos as described previously [117].
For silencing RNA (siRNA) mediated knockdown of
the δ subunit of AP-3, Stealth Select 3 RNAi™ set
(Invitrogen) was ordered. Sequence 3 of this set wasfound to knockdown the δ3 subunit (5′GAGAAGCUGC
CUGUCCAGAAACAUA3′). The ubiquituously expressed
γ1 subunit of AP-1 was knocked down using 5′UAAUAU
AUCAUUCAUAGCU3′ with a 3′ TT overhang. Stealth
RNAi™ siRNA Negative Control Med GC (12935–300;
Invitrogen) was used as a control. The control RNAi was
tagged on the 5′ end with Alexa 647 to determine which
cells were transfected with siRNA. For each 35 mm dish,
200nM of siRNA was transfected using Lipofectamine
2000 according to manufacturer’s instructions. During the
knockdown experiments, 1nM of negative control siRNA
was co transfected with the siRNA against δ3 or γ1 to
confirm the transfection of siRNA into the cell.
DNA Constructs
A cDNA encoding APP 750- yellow fluorescent pro-
tein (YFP) was a kind gift from Dr. Bradley Hyman
(Massachusetts General Hospital). Constructs expressing
full length or shortened (last 112 amino acids) APP (βAPP)
with an amino terminal hemagglutination (HA) tag and
enhanced cyan FP (eCFP) on the carboxyl terminus were
generated as previously described [50]. Plasmids expressing
photoactivatable GFP (paGFP) was a kind gift of Dr.
Jennifer Lippincott-Schwartz [30]. βAPP was recloned
such that paGFP is placed on the C-terminal cytoplasmic
tail of the protein. The Swedish mutation was introduced
into the βAPP-ECFP construct using PCR [50], and was
recloned into the paGFP vector.
Rab5-mRFP, Rab9-mCherry, and LAMP1-mRFP were
generated as previously described [50]. VSVG-paGFP
construct was purchased from Addgene (http://www.
addgene.org).
Confocal microscopy
A Zeiss LSM-510 META laser- scanning microscope
using a Zeiss 63× 1.4 numerical aperture oil immersion
lens was used to take images (Carl Zeiss, Oberkochen,
Germany). The optical section thickness was typically
1 μM. To visualize Alexa Fluor 488 and paGFP fluores-
cence, they were excited with a 488 nm laser and filtered
using a band pass (BP) 500-530-nm emission filter set.
For Alexa Fluor 546, mCherry and mRFP fluorescence, a
543 nm excitation laser and BP 560–615 filter set was
used. To collect ECFP fluorescence, a BP 475–525 emis-
sion filter set was used after excitation with a 458 nm
lasers. Alexa Fluor 647 fluorescence was imaged using
633 nm excitation laser, and a LP 650 filter.
Live cell imaging
For live cell imaging, the cells were washed twice with
PBS, and the culture media was replaced with 37°C
Hank’s Balanced Salt Solution (HBSS; Cat. No. 14025–
092, Invitrogen). To maintain a constant temperature of
37°C, the 35 mm plate was placed on a heated stage
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control 37–2 digital 2-channel (PeCon GmbH).
Using the Ziess Physiology package, regions of interest
(ROI) were selected in the Golgi apparatus, which was
demarcated by GalT-CFP fluorescence and these were
carefully monitored during the experiment to ensure
that they remained over the Golgi apparatus if the cell
or the Golgi apparatus apparatus moved. In a typical ex-
periment, cells were imaged approximately every 30 sec-
onds. For the first 15 minutes, ROIs in the Golgi
apparatus were irradiated with 405 nm laser light to
photoactivate APP-paGFP before imaging. After the initial
15-minute pulse period, images were take without irradi-
ation and the movement/degradation of paGFP fluores-
cence was followed for approximately 45 minutes.
To inhibit APP-paGFP cleavage, cells were treated
with cholorquine (Cat. No. C6628, Sigma) or L685, 458
(Cat. No. 565771, EMD Millipore). Cells were treated with
100 μM choloroquine 30 minutes before imaging to de-
acidify lysosomes. Deacidification of lysosomes was con-
firmed using 75nM Lysosensor™ Green (Cat. No. L-7534,
Invitrogen). To inhibit cleavage using a specific γ-secretase
inhibitor, SN56 cells were treated with 0.5 μM L685, 458
for 24 h before imaging.
Colocalization analysis
Colocalization analysis was performed on using Imaris
7.0 Imaris Colocalization module (Biplane). Imaris soft-
ware was used to create IsoSurfaces corresponding to
the paGFP and RFP fluorescence channels following the
manufacturer’s directions (www.bitplane.com) [118]. This
is a computer assisted method to set fluorescence intensity
thresholds to detect fluorescence in an organellar distri-
bution that can then be used to automatically follow
fluorescence intensity and colocalization over time. The
co-localization of APP and LAMP1 over time was plot-
ted using Prism 5.0 software (Graphpad, La Jolla CA)
and curves were fit using the nonlinear regression by
least squares to fit a one phase exponential decay.
To colocalize AP-3δ and APP we adopted a strategy
we have previously employed [50] and described by
Hutcheon et al. [119] (also discussed in [120,121]), which
sets thresholds based on a fixed percentage of the bright-
est pixels in an image. This allows for the identification of
positive pixels that is unbiased (it does not require the
judgment of the observer on an image to image basis) and
is relatively unaffected by parameters of image acquisition
or the level of protein expression. To colocalize AP-3δ
and APP, the brightest 2% of pixels was selected, and
the percentage of pixels colocalized was recorded [50].
Prism Graphpad 5.0b was used for all graphing and stat-
istical analysis. A One-way ANOVA was performed with
a Dunn’s post-hoc test, and P values under 0.05 were
considered significant.Immunostaining
SN56 cells or mouse cortical neurons were fixed for
15 minutes with 4% paraformaldehyde (Alfa Aesar; Cat
No. 43368). Cells were permeabilized for 5 minutes with
0.1% TritonX-100 in PBS and blocked with 2% BSA for
1 h. Cells were incubated with primary antibodies over-
night at 4°C, washed twice with PBS, and stained with sec-
ondary antibody for 1 h. After staining, confocal plates
were store at 4°C in PBS, and coverslips were mounted
on glass slides with ImmunoMount (Fisher) and stored
at 4°C.
Proximity ligation assay (PLA)
SN56 cells were transiently transfected with βAPP-eCFP,
and fixed for 15 minutes with 4% paraformaldehyde.
Cells were permeabilized and blocked in the same manner
as immunostaining. PLA was performed using a commer-
cially available kit (Duolink; Olink Bioscience) according
to manufacturer’s instructions. Briefly, primary antibodies
were washed off cells with PBS, and species specific PLA
secondary probes were applied to cells. If secondary PLA
probes are within 40 nm of each other, their complemen-
tary DNA strands are ligated and are amplified. Comple-
mentary fluorescent oligonucleotides bind to the amplified
sequence, which results in a fluorescent dot where there
are two interacting proteins.
Cell Lysis and Western Blots
SN56 cells 1.5×106 cells were seeded on 60 mm tissue
culture dishes (Becton Dickinson) and transfected with
plasmids or siRNA using Lipofectamine 2000 according
to manufacturer’s instructions. Cells were harvested in
lysis buffer (1% Nonidet P-40, 150 mm NaCl, 50 mM
Tris-Cl) supplemented with pepstatin and complete pro-
tease inhibitor cocktail (Roche). Lysates were clarified by
centrifugation at 13,000 g for 20 min. To facilitate equal
loading, the total amount of total protein was determined
by bicinchoninic acid (BCA; Thermo Fisher Scientific).
Samples were electrophoresed on SDS-PAGE and trans-
ferred to PVDF membrane (Cat No. 162–01777; Biorad).
Densitometry was performed in ImageJ (NIH), and was
normalized to α-tubulin band density. Graphs were plot-
ted in Prism 5.0b (Graphpad, La Jolla, CA), a one way
ANOVA was performed with a Tukey’s post-hoc test. Re-
sults were significant if p < 0.05.
Additional files
Additional file 1: Figure S1. βAPP-paGFP and full-length APP are
cleaved by that γ-secretase in a similar manner. SN56 cells were
transiently transfected with plasmids expressing GFP, full-length
APPpaGFP (FL-APP-paGFP), or βAPP-paGFP. Twenty-four hours before
harvesting protein for western blotting, cells were treated with DMSO or
with L685, 458. Cell lysate was run on a 12% SDS polyacrylamide gel,
and transferred onto nitrocelluose membrane. Membrane was probed
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reprobed for α-tubulin, as a loading control. Full length APP-paGFP is
cleaved to produce fragments of the predicted size, with a b-cleaved
fragment at ~37 kDA (which is GFP + the 10 kDa b-cleaved APP). The
addition of the γ-secretase inhibitor L685, 458 causes the accumulation
of the 37 kDa band). This pattern is repeated for the shorter
βAPP-paGFP construct.
Additional file 2: Figure S2. Most of the trafficked APP in the cell is
uncleaved. SN56 cells were transiently transfected with plasmids
expressing βAPP-CFP, and immunostained with an anti-HA antibody,
which binds to the HA-epitope on the N-terminus of the construct. In
the merged image, it is possible to see that there is extensive colocalizaition
of the N-terminal HA and the C-terminal CFP tag, implying that much of the
intracellular APP is being trafficked uncleaved.
Additional file 3: Video S1/Figure 1. APP is trafficked rapidly to the
lysosome and cleared. SN56 cells were transiently transfected with
GalT-CFP to identify the Golgi apparatus, LAMP1-mRFP to identify
lysosomes, and βAPP-paGFP. Irradiation targets (circles) were drawn over
the Golgi apparatus and the were irradiated with 405 nm laser light,
alternating with imaging for 15 minutes (indicated by the green word
‘photoactivating’ on the images. Cells were then followed in a ‘chase
period’ imaging every 30 seconds for the time indicated.
Additional file 4: Figure S3. Colocalization of photo-activated
APP-paGFP with LAMP1. SN56 cells were transiently transfected with
plasmids expressing GFP, βAPP-paGFP and GalT-CFP. a) Shows the initial
image of an SN56 cell before photoactivation, with the Golgi apparatus
labelled blue (GalT-CFP) and lysosomes labelled red with LAMP1-mRFP.
Thresholds were set in the red and blue channels to identify the Golgi
apparatus and Lysosomes using Imaris software, and a colocalization
channel is generated and overlaid in white. Although the Golgi apparatus
and Lysosomes are closely apposed, the fluorescent protein markers
demonstrate minimal colocalization. Panel b shows the same cell after
15 minutes of Golgi-targeted photoactivation with activated βAPP-paGFP
in green and lysosomes labelled red with LAMP1-mRFP. The inset is
magnified as figure c. Panel c shows the red LAMP1-mRFP and green
photoactivated βAPP-paGFP channels separately. Thresholds were set in
the red and green channels to identify the lysosomes and the majority of
the APP fluorescent signal using Imaris software, and a colocalization
channel is generated and overlaid in white. This channel demonstrates
extensive colocalization of APP-paGFP and LAMP1. Furthermore, many
regions of APP labelled fluorescence have the same shape as the
underlying LAMP1 label, implying that they are indeed colocalized in
these confocal images.
Additional file 5: Video S2/Figure 1. APP paGFP is accurately
photoactivated in the Golgi apparatus. SN56 cells were transiently
transfected with GalT-CFP to identify the Golgi apparatus, LAMP1-mRFP
to identify lysosomes, and βAPP-paGFP and were treated with Nocodozole
to block exit from the Golgi. Irradiation targets (circles) were drawn over the
Golgi apparatus and the were irradiated with 405 nm laser light, alternating
with imaging for 15 minutes (indicated by the green word ‘photoactivating’
on the images. Cells were then followed in a ‘chase period’ imaging every
30 seconds for the time indicated. Photoactivated βAPP-paGFP can be seen
accumulating in the Golgi.
Additional file 6: Video S3/Figure 3. APP processing in the lysosome
is blocked by Chloroquine in the lysosome. SN56 cells were transiently
transfected with GalT-CFP to identify the Golgi apparatus, LAMP1-mRFP
to identify lysosomes, and βAPP-paGFP. Cells were pretreated with 100 μM
chloroquine 30 minutes before imaging. Irradiation targets (circles) were
drawn over the Golgi apparatus and the were irradiated with 405 nm laser
light, alternating with imaging for 15 minutes (indicated by the green word
‘photoactivating’ on the images. Cells were then followed in a ‘chase period’
imaging every 30 seconds for the time indicated. Photoactivated
βAPP-paGFP can be seen accumulating in lysosomes.
Additional file 7: Video S4/Figure 3. APP processing in the lysosome
is blocked by L685, 458 in the lysosome. SN56 cells were transiently
transfected with GalT-CFP to identify the Golgi apparatus, LAMP1-mRFP
to identify lysosomes, and βAPP-paGFP. Cells were pretreated with
0.5 μM L685, 458 overnight. Irradiation targets (circles) were drawn overthe Golgi apparatus and the were irradiated with 405 nm laser light,
alternating with imaging for 15 minutes (indicated by the green word
‘photoactivating’ on the images. Cells were then followed in a ‘chase
period’ imaging every 30 seconds for the time indicated. Photoactivated
βAPP-paGFP can be seen accumulating in lysosomes.
Additional file 8: Video S5/Figure 4. APPsw trafficking is rapidly
processed. SN56 cells were transiently transfected with GalT-CFP to
identify the Golgi apparatus, LAMP1-mRFP to identify lysosomes, and
βAPPsw-paGFP. Irradiation targets (circles) were drawn over the Golgi
apparatus and the were irradiated with 405 nm laser light, alternating with
imaging for 15 minutes (indicated by the green word ‘photoactivating’ on
the images. Cells were then followed in a ‘chase period’ imaging every
30 seconds for the time indicated. APPsw is cleaved so rapidly that it is
unable to accumulate in any compartment.
Additional file 9: Video S6/Figure 4. APPsw is not cleared in the
Golgi apparatus. SN56 cells were transiently transfected with GalT-CFP to
identify the Golgi apparatus, LAMP1-mRFP to identify lysosomes, and
βAPPsw-paGFP and were treated with 66 μM nocodazole and 10 μM
cytochalasin. Irradiation targets (circles) were drawn over the Golgi
apparatus and the were irradiated with 405 nm laser light, alternating with
imaging for 15 minutes (indicated by the green word ‘photoactivating’ on
the images. Cells were then followed in a ‘chase period’ imaging every
30 seconds for the time indicated. Photoactivated βAPPsw-paGFP can be
seen accumulating in the Golgi.
Additional file 10: Video S7/Figure 5. APPSw processing in the
lysosome is blocked by chloroquine. SN56 cells were transiently
transfected with GalT-CFP to identify the Golgi apparatus, LAMP1-mRFP
to identify lysosomes, and βAPPsw-paGFP and were treated with 100 μM
chloroquine. Irradiation targets (circles) were drawn over the Golgi
apparatus and the were irradiated with 405 nm laser light, alternating
with imaging for 15 minutes (indicated by the green word ‘photoactivating’
on the images. Cells were then followed in a ‘chase period’ imaging every
30 seconds for the time indicated. Photoactivated βAPPsw-paGFP can be
seen accumulating in lysosomes.
Additional file 11: Video S8/Figure 4. APPSw processing in the
lysosome is blocked by L685, 458; γ-cleavage occurs in the lysosome.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi
apparatus, LAMP1-mRFP to identify lysosomes, and βAPPsw-paGFP and
were treated with 0.5 μM L685, 458 overnight. Irradiation targets (circles)
were drawn over the Golgi apparatus and the were irradiated with
405 nm laser light, alternating with imaging for 15 minutes (indicated
by the green word ‘photoactivating’ on the images. Cells were then
followed in a ‘chase period’ imaging every 30 seconds for the time
indicated. Photoactivated βAPPsw-paGFP can be seen accumulating in
lysosomes. (MOV 449 kb)
Additional file 12: Figure S4. Knockdown of AP3 and AP1 by siRNA. a)
SN56 cells were transfected with fluorescently-tagged control siRNA or
AP-3δ and fluorescently tagged siRNA. Western blot demonstrating that
AP-3δ siRNA decreases AP-3δ protein. Blots were stripped and re-probed
with anti-tubulin antibody as a loading control. b) Western blots (from a)
were scanned and analyzed using densitometry (ImageJ) and graphed.
Error bars represents standard error of the mean. (* = p < 0.05). c) SN56
cells were transfected with fluorescently tagged control siRNA or
anti-AP-3δ and fluorescently tagged siRNA (purple). Cells were the
immunostained to detect AP-3δ (red). Fluorescent images overlayed with
white light images to delimit the cell body. (scale bars represents 5 μm).
d) SN56 cells were transfected with control siRNA or siRNA against AP-1γ.
Western blot demonstrating that AP-1γ siRNA decreases AP-1 protein.
Blots were stripped and re-probed with anti-tubulin antibody as a loading
control. e) Western blots (from d) were scanned and analyzed using
densitometry (ImageJ) and graphed. Error bars represents standard error
of the mean. (* = p < 0.05).
Abbreviations
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